Atossa Therapeutics Inc (ATOS)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.52-0.40%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ATOS
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
ATOS — debt issuance
Dated 2026-06-11
Entry into a Material Definitive Agreement. On June 10, 2026, Atossa Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with institutional investors, providing for the issuance and sale by the Company, in a registered direct offering (the “Offering”), of (i) 1,363,638 shares (the “Shares”) of the Company’s common stock, par value $0.18 (“Common Stock”) and (ii) Series A warrants to purchase up to 1,363,638 shares of Common Stock and shor…
Why it matters: How Atossa uses the money from the debt will affect its growth and finances.
Watch forManagement outlines a clear plan for using the proceeds from the recent debt issuance.
Also watch forIf no clear plan is shared, there will be uncertainty about capital use.
Why it matters: Updates on clinical trials can show how well the drug may work. Good news can help investors feel more confident.
Supportive ifThere is news of good trial milestones or positive results for (Z)-endoxifen in studies.
Worry ifDelays in trial progress or bad interim results from ongoing studies.
Why it matters: Higher earnings could show that Atossa is growing and doing better.
Supportive ifQ2 earnings are much better than Q1 results and earlier guidance.
Worry ifQ2 earnings miss expectations or show no improvement from Q1.
Why it matters: Good capital use can improve Atossa's finances and support growth.
Supportive ifA plan or announcement about capital use for the next quarter.
Worry ifNo clear capital allocation plan in the next earnings call.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$265 on $10,000 · ±2.7% | How much price usually moves either way. |
| Bad day | $731 loss on $10,000 · 7.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,011 loss on $10,000 · 90.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Details on debt can affect Atossa's financial health and growth plans.
Worry ifAnnouncement of good terms for the recent debt that helps cash flow.
Less concerning ifBad terms or high interest rates for the debt.
Why it matters: Finishing the offering can give needed funds for clinical development. This affects the company's plans.
Supportive ifThere is news of the successful end of the offering, raising up to $16.5 million.
Worry ifNot finishing the offering or getting much less money than expected.
Why it matters: More equity raises could give needed money for ongoing clinical trials.
Watch forA new equity offering will be announced to raise money for clinical work.
Also watch forNo new equity offerings have been announced, even with ongoing funding needs.
Why it matters: Clear capital plans could show better financial health and growth.
Supportive ifManagement will share a detailed capital plan in the next earnings call.
Worry ifThere was no clear plan for capital. This caused uncertainty for investors.
Why it matters: Settling patent disputes can help Atossa's market position. It can also lower legal risks.
Supportive ifA settlement is reached that ends all current patent disputes.
Worry ifNew patent lawsuits are filed or old disputes are still not resolved.
Why it matters: Settling patent disputes can help Atossa's plans and position in the market.
Supportive ifA settlement was announced with a big competitor in the patent dispute.
Worry ifNo progress on settlements means longer legal disputes.
Why it matters: A clear capital plan can show Atossa's financial health and growth potential.
Watch forManagement has a clear plan for capital. It includes new investments.
Also watch forNo clear capital plan is shared at the next earnings call.
Why it matters: Good feedback could speed up the work on (Z)-endoxifen for Duchenne Muscular Dystrophy.
Supportive ifFDA gives good feedback on the (Z)-endoxifen plan for DMD.
Worry ifFDA issues concerns or delays feedback on (Z)-endoxifen for DMD.
Why it matters: New data could strengthen the case for (Z)-endoxifen in rare diseases. This may attract investor interest and support future funding.
Supportive ifA press release shows good clinical trial results for (Z)-endoxifen. This is for Duchenne Muscular Dystrophy or McCune-Albright Syndrome.
Worry ifNo new data or negative trial results for (Z)-endoxifen in these diseases.
Why it matters: Settlements could lower legal costs. This would help focus on product development.
Supportive ifAtossa says it has settled its patent disputes.
Worry ifAtossa has ongoing lawsuits with no end and rising legal costs.